Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
10.68 USD   +0.56%
11/09Transcript : ALX Oncology Holdings Inc. Presents at Credit Suisse 31st Annual Healthcare Conference, Nov-09-2022 09:50 AM
CI
11/09HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains Buy Rating
MT
11/08ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

10/05/2022 | 08:02am EST

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the acceptance of two Trials in Progress abstracts related to ASPEN-03 and ASPEN-04, the Company’s Phase 2 head and neck cancer studies in collaboration with Merck (known as MSD outside the US and Canada), at the SITC 37th Annual Meeting in Boston, MA, from November 8–12, 2022.

Poster Presentation Details

Title: A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03
Abstract Number: 678
Session Date and Time: November 10-11, 2022, from 9:00 am – 9:00 pm ET
Location: Poster Hall

Title: A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04
Abstract Number: 676
Session Date and Time: November 10-11, 2022, from 9:00 am – 9:00 pm ET
Location: Poster Hall

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.


All news about ALX ONCOLOGY HOLDINGS INC.
11/09Transcript : ALX Oncology Holdings Inc. Presents at Credit Suisse 31st Annual..
CI
11/09HC Wainwright Lowers Price Target on ALX Oncology Holdings to $65 From $80, Maintains B..
MT
11/08ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
11/08ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Develop..
GL
11/08ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Develop..
AQ
11/08ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/03ALX Oncology to Present New Clinical Data on Evorpacept ináAcute Myeloid Leukemia at 64..
GL
11/02ALX Oncology Announces Upcoming Investor Conference Participation
GL
10/31ALX Oncology Secures $100 Million Loan Facility Deal
MT
10/31Alx Oncology Holdings Inc : Entry into a Material Definitive Agreement, Creation of a Dire..
AQ
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -131 M - -
Net cash 2022 255 M - -
P/E ratio 2022 -3,36x
Yield 2022 -
Capitalization 435 M 435 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 55
Free-Float 73,6%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 10,68 $
Average target price 35,00 $
Spread / Average Target 228%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. GarcÝa Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-50.30%435
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930